<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1016/j.joca.2022.02.587</dc:identifier><dc:language>eng</dc:language><dc:creator>Paesa, M.</dc:creator><dc:creator>Remírez de Ganuza, C.</dc:creator><dc:creator>García-Álvarez, F.</dc:creator><dc:creator>Irusta, S.</dc:creator><dc:creator>Arruebo, M.</dc:creator><dc:creator>Mendoza, G.</dc:creator><dc:title>The reversion of osteoarthritis-like alterations by raloxifene and phloretin in lipopolysaccharide-induced chondrogenic cell lines</dc:title><dc:identifier>ART-2022-141303</dc:identifier><dc:description>Purpose: Osteoarthritis (OA) is a chronic joint disease characterized by cartilage degradation, alterations in bone formation or subchondral bone remodeling and progressive synovial inflammation. Inflammatory signaling is involved in OA pathophysiology...</dc:description><dc:date>2022</dc:date><dc:source>http://zaguan.unizar.es/record/147892</dc:source><dc:doi>10.1016/j.joca.2022.02.587</dc:doi><dc:identifier>http://zaguan.unizar.es/record/147892</dc:identifier><dc:identifier>oai:zaguan.unizar.es:147892</dc:identifier><dc:identifier.citation>Osteoarthritis and cartilage 30, Suppl. 1 (2022), S430-S431</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>